COVID-19 & Psychiatry: A Retrospective Chart Review

Sponsor

Northwestern University (Other)

Overall Status

Enrolling by invitation

CT.gov ID

NCT05244096

Collaborator

(none)

65,000

Enrollment

Location

6.5

Anticipated Duration (Months)

9941.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A retrospective chart review study to determine the effects of psychotropic medications and prior psychiatric diagnoses on COVID-19 patients' disease progression, and severity.

Condition or Disease	Intervention/Treatment	Phase
COVID-19	Other: No intervention

Detailed Description

The goal of this study would be to study the association between use of psychotropic medications and prior psychiatric diagnoses on COVID-19 patients' disease progression and severity.

Study Design

Study Type:

Observational

Anticipated Enrollment :

65000 participants

Observational Model:

Other

Time Perspective:

Retrospective

Official Title:

A Retrospective Chart Review Study to Determine the Effects of Psychotropic Medications and Prior Psychiatric Diagnoses on COVID-19 Patients' Disease Progression, and Severity.

Actual Study Start Date :

Jan 12, 2022

Anticipated Primary Completion Date :

Jun 30, 2022

Anticipated Study Completion Date :

Jul 30, 2022

Arms and Interventions

Arm	Intervention/Treatment
COVID+ COVID + positive individuals from March 15 2020 to Nov 30, 2021	Other: No intervention Observational study

Arm

Intervention/Treatment

COVID+

COVID + positive individuals from March 15 2020 to Nov 30, 2021

Other: No intervention

Observational study

Outcome Measures

Primary Outcome Measures

Hazard Ratio [March 15 2020 to Nov 30 2021]
HR of using psych drugs or having psych diagnosis

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Individuals with a positive COVID-19 test between March 15 2020 to November 30 2021 at Northwestern Medicine hospitals.

Exclusion Criteria:

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Northwester Clinical Research Program	Chicago	Illinois	United States	60611

Sponsors and Collaborators

Northwestern University

Investigators

Principal Investigator: Jeffrey Rado, MD, Northwestern University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Jeffrey Rado, Associate Professor, Northwestern University

ClinicalTrials.gov Identifier:

NCT05244096

Other Study ID Numbers:

STU00214993

First Posted:

Feb 17, 2022

Last Update Posted:

Jun 9, 2022

Last Verified:

Jun 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

COVID-19

Study Results

No Results Posted as of Jun 9, 2022